• Inhibrx Biosciences entered a second amendment to its loan and security agreement with Oxford Finance, expanding the credit facility to USD 500 million.
• New tranche adds up to USD 325 million; USD 100 million funded at signing as a Term C Loan.
• Up to USD 225 million more available as a Term D Loan in USD 50 million minimum draws, subject to lenders’ discretion.
• Company had already drawn USD 175 million under the facility before the amendment.
• Lenders received warrants for 21,457 shares at a USD 93.21 strike price, equal to 2% of the Term C Loan value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05812) on July 16, 2026, and is solely responsible for the information contained therein.